Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

National Cancer Institute (NCI)162 enrolled

Overview

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of congestive heart failure (CHF) in patients from the clinical trial ECOG-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.

Study Type

OBSERVATIONAL

Enrollment

162

Conditions

Breast Carcinoma

Interventions

Laboratory Biomarker AnalysisOTHER

Correlative studies

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

Outcomes

Primary Outcomes

Identification of rare coding variants of large effect that predict the risk of CHF

Assessed by burden analysis.

Time frame: Baseline